NCT00275548View on ClinicalTrials.gov

Safety and Effectiveness Using Pegasys and Copegus in Recipients of Liver Transplantation With Hepatitis C

PHASE4CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

June 30, 2007

Study Completion Date

April 30, 2009

Conditions

Liver TransplantHepatitis C

Interventions

DRUG

Pegasys

135-180 micrograms administered sc once weekly

DRUG

Copegus

400-1200 mg/day for 48 weeks

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Roche Pharma AG

INDUSTRY

lead

Mayo Clinic

OTHER